Acyclic CB1 Receptor Blockers With Restricted Brain Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CB1 receptor blockers, such as rimonabant, are effective in treating obesity and metabolic syndromes but cause CNS-mediated side effects, leading to their withdrawal from the market, necessitating the development of peripherally restricted CB1 receptor antagonists that do not penetrate the blood-brain barrier.
Innovation Solution
Designing novel lipophilic CB1 receptor-binding compounds that are P-gp substrates, have a brain/plasma ratio below 0.3, and contain a diphenyl ethylene or diphenyl methylene moiety, which limit brain penetration and provide therapeutic benefits without CNS side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If globally acting CB1 receptor blockers are used, then therapeutic benefits for obesity and metabolic syndromes are achieved, but CNS-mediated side effects occur
Solution Approach 1:
The patent segments the CB1 receptor blockade action into peripheral and central components by designing compounds that selectively target peripheral CB1 receptors while excluding central nervous system penetration. This is achieved through molecular structures that are substrates for P-glycoprotein efflux pumps at the blood-brain barrier, effectively dividing the drug's action zone to eliminate CNS side effects while preserving metabolic therapeutic benefits
Solution Approach 2:
The invention applies local quality by creating compounds with specific molecular characteristics (lipophilicity balanced with P-gp substrate properties) that enable selective peripheral action. The compounds possess structural features (such as specific heterocyclic rings and side chain configurations) that confer high affinity for peripheral CB1 receptors while simultaneously being recognized by P-gp transporters to prevent brain entry, thus achieving localized therapeutic action
2Object-affected harmful factors
If peripherally restricted CB1 receptor antagonists are designed, then CNS side effects are avoided, but development complexity increases
Solution Approach 1:
The patent employs parameter changes by systematically modifying molecular properties of CB1 antagonists, specifically adjusting lipophilicity (logP values), molecular weight, and structural features to achieve the optimal balance between peripheral efficacy and brain penetration resistance. The invention identifies specific parameter ranges (e.g., logP between 2-5, specific heterocyclic ring structures) that confer P-gp substrate status while maintaining CB1 binding affinity, providing a framework for designing peripherally restricted compounds
Data Source
AI summary
The invention generally concerns a novel class of CB1 receptor binding molecules and uses thereof.